SmellTaste statement on Dupilumab approval for eligible NHS England patients with severe CRSwNP
SmellTaste is delighted that Dupilumab has been approved for eligible* NHS England patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP), a long-term inflammatory condition that has a profound impact on quality of life and is a leading cause of smell loss.
SmellTaste has been a stakeholder in the appraisal process led by National Institute for Health and Care Excellence (NICE). We have consistently highlighted the significant unmet need faced by people living with severe CRSwNP, particularly those for whom the existing gold standard treatment, sinus surgery, fails to provide lasting relief from symptoms.
Commenting on the decision, Duncan Boak, CEO and Founder of SmellTaste, said:
I’m very pleased that Dupilumab is finally available to treat eligible people in the UK with the most severe cases of a chronic disease that is one of the biggest causes of smell loss. I hope this helps paves the way for greater recognition and further NICE-approved treatments for the many people living with chronic rhinosinusitis, which affects around 11% of the UK population.
SmellTaste contributed a body of evidence to the NICE appraisal based on focus group meetings and surveys with our members which highlighted how significantly the disease affects people’s lives, particularly the wide-ranging impact of smell loss. We would like to thank all of our beneficiaries who have contributed to our evidence submission along with our patient expert Sophie for representing the views of patients in the NICE committee meetings.
SmellTaste is encouraged that people with the most severe forms of CRSwNP in the UK will now have access to a targeted treatment option that has already transformed care of those in many other countries. We remain committed to working with clinicians, policymakers and patient communities to ensure that the impact of impaired smell and taste impairment is recognised and addressed in future health decision-making.
*Dupilumab can be prescribed to NHS England patients who meet all of the following criteria:
- the condition is not controlled well enough by systemic corticosteroids or sinus surgery, and
- they have had at least 1 sinus surgery, and
- the 22-item sinonasal outcomes test (SNOT-22) score is at least 50
The final draft guidance can be viewed on the NICE website.
If you believe you may be eligible to be prescribed Dupilumab you should speak with your ENT Consultant in the first instance. The SNOT-22 survey is a self-administered questionnaire used to assess the impact of chronic rhinosinusitis and nasal polyps on a patient’s quality of life. It is typically used as part of ENT Consultations. The CRS section of the EUFOREA website contains some helpful information about preparing for your consultation. It includes a sample of the SNOT-22 survey.



















